Emglif-L™

Therapeutic Segment:
Anti-diabetic

Generic Name:
Empagliflozin/Linagliptin

Description:
Emglif™-L tablet combines two antihyperglycemic medicinal products with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: empagliflozin, a sodium-glucose co-transporter (SGLT2) inhibitor, and linagliptin, DPP-4 inhibitor.

Indication:
Empagliflozin + Linagliptin, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus.

• To improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Empagliflozin+Linagliptin do not provide adequate glycaemic control.
• When already being treated with the free combination of empagliflozin and linagliptin.

Formulation:

• Tablets

Strength:

• 10mg/5mg
• 25mg/5mg

Pack Size:

• 28’s
• 28’s